Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg raises target price on Pinewood Technologies

(Sharecast News) - Analysts at Berenberg raised their target price on software firm Pinewood Technologies from 455.0p to 510.0p on Friday after the group's FY24 earnings came in ahead of consensus. Pinewood Technologies said in its trading update for the 11-month period to 31 December that it now expects FY24 adjusted pre-tax profits to be ahead of analyst expectations.

Additionally, it also announced a major new contract win with Global Auto Holdings, which has 155 franchise dealers across the UK, North America and Scandinavia, as well as a larger network of dealers.

"There are a few moving parts with respect to FY25 and FY26E forecasts. Pinewood has flagged that it expects the implementation of recently signed customers, to be weighted more towards FY26 than FY25. This leads to a shift of revenue and profits to the right. In addition, the first full year of annualised contribution from today's contract win will be in FY27E. As a result, we decrease our FY26E adjusted EPS forecast by c7% and increase our FY27E adjusted EPS by c9%," said the German bank, which has a 'buy' rating on the stock.

Berenberg also noted that Pinewood's shares were currently trading on an FY25 price-to-earnings ratio of roughly 35x.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.